This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Atreca aumenten en un 4.3% al año. Se prevé que el BPA aumente en un 20.7% al año.

Información clave

4.3%

Tasa de crecimiento de los beneficios

20.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	31 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:BCEL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-52	N/A	N/A	1
12/31/2025	N/A	-48	N/A	N/A	1
12/31/2024	N/A	-38	N/A	N/A	1
12/31/2023	N/A	-65	N/A	N/A	1
9/30/2023	N/A	-98	-65	-65	N/A
6/30/2023	N/A	-85	-65	-64	N/A
3/31/2023	N/A	-93	-71	-70	N/A
12/31/2022	N/A	-97	-82	-81	N/A
9/30/2022	N/A	-105	-86	-81	N/A
6/30/2022	N/A	-110	-88	-81	N/A
3/31/2022	N/A	-108	-93	-69	N/A
12/31/2021	N/A	-109	-96	-61	N/A
9/30/2021	N/A	-103	-96	-63	N/A
6/30/2021	N/A	-98	-93	-62	N/A
3/31/2021	N/A	-92	-82	-66	N/A
12/31/2020	N/A	-86	-72	-67	N/A
9/30/2020	N/A	-83	-70	-65	N/A
6/30/2020	N/A	-76	-71	-65	N/A
3/31/2020	N/A	-74	-67	-63	N/A
12/31/2019	N/A	-67	-62	-59	N/A
9/30/2019	N/A	-59	-56	-53	N/A
6/30/2019	N/A	-53	-47	-45	N/A
3/31/2019	N/A	-44	-41	-40	N/A
12/31/2018	N/A	-38	-36	-35	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BCEL siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BCEL siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BCEL siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de BCEL crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: Se prevé que BCEL no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BCEL se prevé que sea elevada dentro de 3 años.

This company listing is no longer active

Atreca Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 24% to US$9.44

Price target increased to US$15.57

Price target decreased to US$16.63

Price target decreased to US$19.56

Price target decreased to US$25.33

Analysts update estimates

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento